Localization of mutant ubiquitin in the brain of a transgenic mouse line with proteasomal inhibition and its validation at specific sites in Alzheimer’s disease

Frontiers in Neuroanatomy

Volumn 9, Issue MAR, 2015, Pages

  Gentier, Romina J G ^a   Verheijen, Bert M ^a   Zamboni, Margherita ^a   Stroeken, Maartje M A ^a   Hermes, Denise J H P ^a   Küsters, Benno ^b,c   Steinbusch, Harry W M ^a   Hopkins, David A ^a,d   Van Leeuwen, Fred W ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^d DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Basal ganglia; Frameshift mutation; Inferior colliculus; Nucleus basalis of Meynert; Olfactory bulb; Raphe nuclei; RNA; Ubiquitin B+1

Indexed keywords

PROTEASOME; UBIQUITIN;

ADULT; AGED; ALZHEIMER DISEASE; AMYGDALOID NUCLEUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BASAL GANGLION; BRAIN; BRAIN CORTEX; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DENTATE GYRUS; DIENCEPHALON; GENE MAPPING; GENE MUTATION; GENE OVEREXPRESSION; GENETIC ASSOCIATION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; INFERIOR COLLICULUS; MALE; MEDULLA OBLONGATA; MESENCEPHALON; MEYNERT BASAL NUCLEUS; MICROSCOPY; MIDDLE AGED; MOUSE; NONHUMAN; OLFACTORY BULB; PARABRACHIAL NUCLEUS; RAPHE NUCLEUS; SOLITARY TRACT NUCLEUS; TELENCEPHALON; UBIQUITINATION; VERY ELDERLY;

EID: 84927713963     PISSN: None     EISSN: 16625129     Source Type: Journal    
DOI: 10.3389/fnana.2015.00026     Document Type: Article

References (65)

1. Attems, J., Walker, L., and Jellinger, K. A. (2014). Olfactory bulb involvement in neurodegenerative diseases. Acta Neuropathol. 127, 459-475. doi: 10.1007/s00401-014-1261-7
2. Baloyannis, S. J., Mauroudis, I., Manolides, S. L., and Manolides, L. S. (2009). Synaptic alterations in the medial geniculate bodies and the inferior colliculi in Alzheimer's disease: a Golgi and electron microscope study. Acta Otolaryngol. 129, 416-418. doi: 10.1080/00016480802579074
3. Barnes, D. E., and Yaffe, K. (2011). The projected effect of risk factor reduction on Alzheimer's disease prevalence. Lancet Neurol. 10, 819-828. doi: 10.1016/S1474-4422(11)70072-2
4. Braak, H., Del Tredici, K., Rub, U., De Vos, R. A., Jansen Steur, E. N., and Braak, E. (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197-211. doi: 10.1016/S0197-4580(02)00065-9
5. Braak, H., Thal, D. R., Ghebremedhin, E., and Del Tredici, K. (2011). Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years. J. Neuropathol. Exp. Neurol. 70, 960-969. doi: 10.1097/NEN.0b013e318232a379
6. Brilliant, M. J., Elble, R. J., Ghobrial, M., and Struble, R. G. (1997). The distribution of amyloid beta protein deposition in the corpus striatum of patients with Alzheimer's disease. Neuropathol. Appl. Neurobiol. 23, 322-325. doi: 10.1111/j.1365-2990.1997.tb01302.x
7. Burns, J. M., Mayo, M. S., Anderson, H. S., Smith, H. J., and Donnelly, J. E. (2008). Cardiorespiratory fitness in early-stage Alzheimer disease. Alzheimer Dis. Assoc. Disord. 22, 39-46. doi: 10.1097/WAD.0b013e31815a9ddc
8. Cereda, E., Cilia, R., Klersy, C., Canesi, M., Zecchinelli, A. L., Mariani, C. B., et al. (2014). Swallowing disturbances in Parkinson's disease: a multivariate analysis of contributing factors. Parkinsonism Relat. Disord. 20, 1382-1387. doi: 10.1016/j.parkreldis.2014.09.031
9. Corder, E. H., Saunders, A. M., Strittmatter, W. J., Schmechel, D. E., Gaskell, P. C., Small, G. W., et al. (1993). Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261, 921-923. doi: 10.1126/science.8346443
10. De Jong, L. W., Ferrarini, L., Van Der Grond, J., Milles, J. R., Reiber, J. H., Westendorp, R. G., et al. (2011). Shape abnormalities of the striatum in Alzheimer's disease. J. Alzheimers Dis 23, 49-59. doi: 10.3233/JAD-2010-101026
11. Del Tredici, K., Rub, U., De Vos, R. A., Bohl, J. R., and Braak, H. (2002). Where does parkinson disease pathology begin in the brain? J. Neuropathol. Exp. Neurol. 61, 413-426.
12. Dennissen, F. J., Kholod, N., and Van Leeuwen, F. W. (2012). The ubiquitin proteasome system in neurodegenerative diseases: culprit, accomplice or victim? Prog. Neurobiol. 96, 190-207. doi: 10.1016/j.pneurobio.2012.01.003
13. De Pril, R., Fischer, D. F., Maat-Schieman, M. L., Hobo, B., De Vos, R. A., Brunt, E. R., et al. (2004). Accumulation of aberrant ubiquitin induces aggregate formation and cell death in polyglutamine diseases. Hum. Mol. Genet. 13, 1803-1813. doi: 10.1093/hmg/ddh188
14. Djordjevic, J., Jones-Gotman, M., De Sousa, K., and Chertkow, H. (2008). Olfaction in patients with mild cognitive impairment and Alzheimer's disease. Neurobiol. Aging 29, 693-706. doi: 10.1016/j.neurobiolaging.2006.11.014
15. Dugger, B. N., Tu, M., Murray, M. E., and Dickson, D. W. (2011). Disease specificity and pathologic progression of tau pathology in brainstem nuclei of Alzheimer's disease and progressive supranuclear palsy. Neurosci. Lett. 491, 122-126. doi: 10.1016/j.neulet.2011.01.020
16. Duyckaerts, C., Delatour, B., and Potier, M. C. (2009). Classification and basic pathology of Alzheimer disease. Acta Neuropathol. 118, 5-36. doi: 10.1007/s00401-009-0532-1
17. Fischer, D. F., De Vos, R. A., Van Dijk, R., De Vrij, F. M., Proper, E. A., Sonnemans, M. A., et al. (2003). Disease-specific accumulation of mutant ubiquitin as a marker for proteasomal dysfunction in the brain. FASEB J. 17, 2014-2024. doi: 10.1096/fj.03-0205com
18. Fischer, D. F., Van Dijk, R., Van Tijn, P., Hobo, B., Verhage, M. C., Van Der Schors, R. C., et al. (2009). Long-term proteasome dysfunction in the mouse brain by expression of aberrant ubiquitin. Neurobiol. Aging 30, 847-863. doi: 10.1016/j.neurobiolaging.2008.06.009
19. Franklin, K. B. J., and Paxinos, J. (2007). The Mouse Brain in Stereotaxic Coordinates. Amsterdam: Elsevier.
20. Geerlings, M. I., Den Heijer, T., Koudstaal, P. J., Hofman, A., and Breteler, M. M. (2008). History of depression, depressive symptoms, and medial temporal lobe atrophy and the risk of Alzheimer disease. Neurology 70, 1258-1264. doi: 10.1212/01.wnl.0000308937.30473.d1
21. Grinberg, L. T., Rub, U., Ferretti, R. E., Nitrini, R., Farfel, J. M., Polichiso, L., et al. (2009). The dorsal raphe nucleus shows phospho-tau neurofibrillary changes before the transentorhinal region in Alzheimer's disease. A precocious onset? Neuropathol. Appl. Neurobiol. 35, 406-416. doi: 10.1111/j.1365-2990.2008.00997.x
22. Guerin, D., Sacquet, J., Mandairon, N., Jourdan, F., and Didier, A. (2009). Early locus coeruleus degeneration and olfactory dysfunctions in Tg2576 mice. Neurobiol. Aging 30, 272-283. doi: 10.1016/j.neurobiolaging.2007.05.020
23. Haines, D. E. (2011). Neuroanatomy: An Atlas of Structures, Sections and Systems. Philadelphia, PA: Wolters Kluwer/Lippincott Williams & Wilkins Health.
24. Hammerschmidt, T., Kummer, M. P., Terwel, D., Martinez, A., Gorji, A., Pape, H. C., et al. (2013). Selective loss of noradrenaline exacerbates early cognitive dysfunction and synaptic deficits in APP/PS1 mice. Biol. Psychiatry 73, 454-463. doi: 10.1016/j.biopsych.2012.06.013
25. Heneka, M. T., Ramanathan, M., Jacobs, A. H., Dumitrescu-Ozimek, L., Bilkei-Gorzo, A., Debeir, T., et al. (2006). Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J. Neurosci. 26, 1343-1354. doi: 10.1523/JNEUROSCI.4236-05.2006
26. Holton, P., Ryten, M., and Nalls, M. (2013). Initial assessment of the pathogenic mechanisms of the recently identified Alzheimer risk Loci. Ann. Hum. Genet. 77, 85-105. doi: 10.1111/ahg.12000
27. Idrizbegovic, E., Hederstierna, C., Dahlquist, M., Kampfe Nordstrom, C., Jelic, V., and Rosenhall, U. (2011). Central auditory function in early Alzheimer's disease and in mild cognitive impairment. Age Ageing 40, 249-254. doi: 10.1093/ageing/afq168
28. International Genomics of Alzheimer's Disease Consortium (IGAP). (2015). Convergent genetic and expression data implicate immunity in Alzheimer's disease. Alzheimers Dement. 1-14. doi: 10.1016/j.jalz.2014.05.1757. [Epub ahead of print].
29. Irmler, M., Gentier, R. J., Dennissen, F. J., Schulz, H., Bolle, I., Holter, S. M., et al. (2012). Long-term proteasomal inhibition in transgenic mice by UBB(+1) expression results in dysfunction of central respiration control reminiscent of brainstem neuropathology in Alzheimer patients. Acta Neuropathol. 124, 187-197. doi: 10.1007/s00401-012-1003-7
30. Jankowsky, J. L., Fadale, D. J., Anderson, J., Xu, G. M., Gonzales, V., Jenkins, N. A., et al. (2004). Mutant presenilins specifically elevate the levels of the 42 residue beta-amyloid peptide in vivo: evidence for augmentation of a 42-specific gamma secretase. Hum. Mol. Genet. 13, 159-170. doi: 10.1093/hmg/ddh019
31. Jellinger, K. A. (2014). The cholinergic basal forebrain in Lewy body dementia and Alzheimer's disease. J. Neurol. 262, 479-480. doi: 10.1007/s00415-014-7610-6
32. Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P. V., Snaedal, J., et al. (2013). Variant of TREM2 associated with the risk of Alzheimer's disease. N. Engl. J. Med. 368, 107-116. doi: 10.1056/NEJMoa1211103
33. Jucker, M., and Walker, L. C. (2011). Pathogenic protein seeding in Alzheimer disease and other neurodegenerative disorders. Ann. Neurol. 70, 532-540. doi: 10.1002/ana.22615
34. Krutauz, D., Reis, N., Nakasone, M. A., Siman, P., Zhang, D., Kirkpatrick, D. S., et al. (2014). Extended ubiquitin species are protein-based DUB inhibitors. Nat. Chem. Biol. 10, 664-670. doi: 10.1038/nchembio.1574
35. Mai, J. K., and Paxinos, G. (2012). The Human Nervous System. Amsterdam: Elsevier Science
36. Mai, J. K., Paxinos, G., and Voss, T. (2008). Atlas of the Human Brain. Amsterdam: Academic Press.
37. Manavalan, A., Mishra, M., Feng, L., Sze, S. K., Akatsu, H., and Heese, K. (2013). Brain site-specific proteome changes in aging-related dementia. Exp. Mol. Med. 45, e39. doi: 10.1038/emm.2013.76
38. Mayford, M., Bach, M. E., Huang, Y. Y., Wang, L., Hawkins, R. D., and Kandel, E. R. (1996a). Control of memory formation through regulated expression of a CaMKII transgene. Science 274, 1678-1683. doi: 10.1126/science.274.5293.1678
39. Mayford, M., Bach, M. E., and Kandel, E. (1996b). CaMKII function in the nervous system explored from a genetic perspective. Cold Spring Harb. Symp. Quant. Biol. 61, 219-224. doi: 10.1101/SQB.1996.061.01.024
40. Mesulam, M. M. (2013). Cholinergic circuitry of the human nucleus basalis and its fate in Alzheimer's disease. J. Comp. Neurol. 521, 4124-4144. doi: 10.1002/cne.23415
41. Mesulam, M., Shaw, P., Mash, D., and Weintraub, S. (2004). Cholinergic nucleus basalis tauopathy emerges early in the aging-MCI-AD continuum. Ann. Neurol. 55, 815-828. doi: 10.1002/ana.20100
42. Mitchell, R. A., Herrmann, N., and Lanctot, K. L. (2011). The role of dopamine in symptoms and treatment of apathy in Alzheimer's disease. CNS Neurosci. Ther. 17, 411-427. doi: 10.1111/j.1755-5949.2010.00161.x
43. Mobley, A. S., Rodriguez-Gil, D. J., Imamura, F., and Greer, C. A. (2014). Aging in the olfactory system. Trends Neurosci. 37, 77-84. doi: 10.1016/j.tins.2013.11.004
44. Murray, A. M., Weihmueller, F. B., Marshall, J. F., Hurtig, H. I., Gottleib, G. L., and Joyce, J. N. (1995). Damage to dopamine systems differs between Parkinson's disease and Alzheimer's disease with parkinsonism. Ann. Neurol. 37, 300-312. doi: 10.1002/ana.410370306
45. Ohm, T. G., and Braak, H. (1987). Olfactory bulb changes in Alzheimer's disease. Acta Neuropathol. 73, 365-369. doi: 10.1007/BF00688261
46. Ohm, T. G., and Braak, H. (1989). Auditory brainstem nuclei in Alzheimer's disease. Neurosci. Lett. 96, 60-63. doi: 10.1016/0304-3940(89)90243-7
47. Parvizi, J., Van Hoesen, G. W., and Damasio, A. (2001). The selective vulnerability of brainstem nuclei to Alzheimer's disease. Ann. Neurol. 49, 53-66. doi: 10.1002/1531-8249(200101)49:1<53::AID-ANA30>3.0.CO;2-Q
48. Petry, F. R., Pelletier, J., Bretteville, A., Morin, F., Calon, F., Hebert, S. S., et al. (2014). Specificity of anti-tau antibodies when analyzing mice models of Alzheimer's disease: problems and solutions. PLoS ONE 9:e94251. doi: 10.1371/journal.pone.0094251
49. Ressler, K. J., and Nemeroff, C. B. (2000). Role of serotonergic and noradrenergic systems in the pathophysiology of depression and anxiety disorders. Depress. Anxiety 12(Suppl. 1), 2-19. doi: 10.1002/1520-6394(2000)12:1+<2::AID-DA2>3.0.CO;2-4
50. Rey, N. L., Jardanhazi-Kurutz, D., Terwel, D., Kummer, M. P., Jourdan, F., Didier, A., et al. (2012). Locus coeruleus degeneration exacerbates olfactory deficits in APP/PS1 transgenic mice. Neurobiol. Aging 33, 426 e1-426 e11. doi: 10.1016/j.neurobiolaging.2010.10.009
51. Rub, U., Del Tredici, K., Schultz, C., Thal, D. R., Braak, E., and Braak, H. (2000). The evolution of Alzheimer's disease-related cytoskeletal pathology in the human raphe nuclei. Neuropathol. Appl. Neurobiol. 26, 553-567. doi: 10.1046/j.0305-1846.2000.00291.x
52. Schipanski, A., Oberhauser, F., Neumann, M., Lange, S., Szalay, B., Krasemann, S., et al. (2014). The lectin OS-9 delivers mutant neuroserpin to endoplasmic reticulum associated degradation in familial encephalopathy with neuroserpin inclusion bodies. Neurobiol. Aging 35, 2394-2403. doi: 10.1016/j.neurobiolaging.2014.04.002
53. Selkoe, D. J. (2001). Alzheimer's disease: genes, proteins, and therapy. Physiol. Rev. 81, 741-766.
54. Sierksma, A. S., Van Den Hove, D. L., Steinbusch, H. W., and Prickaerts, J. (2010). Major depression, cognitive dysfunction and Alzheimer's disease: is there a link? Eur. J. Pharmacol. 626, 72-82. doi: 10.1016/j.ejphar.2009.10.021
55. Sinha, U. K., Hollen, K. M., Rodriguez, R., and Miller, C. A. (1993). Auditory system degeneration in Alzheimer's disease. Neurology 43, 779-785. doi: 10.1212/WNL.43.4.779
56. Suenaga, T., Hirano, A., Llena, J. F., Yen, S. H., and Dickson, D. W. (1990). Modified Bielschowsky stain and immunohistochemical studies on striatal plaques in Alzheimer's disease. Acta Neuropathol. 80, 280-286. doi: 10.1007/BF00294646
57. Van Leeuwen, F. W., De Kleijn, D. P., Van Den Hurk, H. H., Neubauer, A., Sonnemans, M. A., Sluijs, J. A., et al. (1998). Frameshift mutants of beta amyloid precursor protein and ubiquitin-B in Alzheimer's and Down patients. Science 279, 242-247.
58. Van Leeuwen, F. W., Fischer, D. F., Kamel, D., Sluijs, J. A., Sonnemans, M. A., Benne, R., et al. (2000). Molecular misreading: a new type of transcript mutation expressed during aging. Neurobiol. Aging 21, 879-891. doi: 10.1016/S0197-4580(00)00151-2
59. Van Leeuwen, F. W., Van Tijn, P., Sonnemans, M. A., Hobo, B., Mann, D. M., Van Broeckhoven, C., et al. (2006). Frameshift proteins in autosomal dominant forms of Alzheimer disease and other tauopathies. Neurology 66, S86-92. doi: 10.1212/01.wnl.0000193882.46003.6d
60. Van Tijn, P., Dennissen, F. J., Gentier, R. J., Hobo, B., Hermes, D., Steinbusch, H. W., et al. (2012). Mutant ubiquitin decreases amyloid beta plaque formation in a transgenic mouse model of Alzheimer's disease. Neurochem. Int. 61, 739-748. doi: 10.1016/j.neuint.2012.07.007
61. Van Tijn, P., De Vrij, F. M., Schuurman, K. G., Dantuma, N. P., Fischer, D. F., Van Leeuwen, F. W., et al. (2007). Dose-dependent inhibition of proteasome activity by a mutant ubiquitin associated with neurodegenerative disease. J. Cell Sci. 120, 1615-1623. doi: 10.1242/jcs.03438
62. Van Tijn, P., Hobo, B., Verhage, M. C., Oitzl, M. S., Van Leeuwen, F. W., and Fischer, D. F. (2011). Alzheimer-associated mutant ubiquitin impairs spatial reference memory. Physiol. Behav. 102, 193-200. doi: 10.1016/j.physbeh.2010.11.001
63. Vidoni, E. D., Honea, R. A., Billinger, S. A., Swerdlow, R. H., and Burns, J. M. (2012). Cardiorespiratory fitness is associated with atrophy in Alzheimer's and aging over 2 years. Neurobiol. Aging 33, 1624-1632. doi: 10.1016/j.neurobiolaging.2011.03.016
64. Whitehouse, P. J., Price, D. L., Struble, R. G., Clark, A. W., Coyle, J. T., and Delon, M. R. (1982). Alzheimer's disease and senile dementia: loss of neurons in the basal forebrain. Science 215, 1237-1239. doi: 10.1126/science.7058341
65. Wilson, R. S., Mendes De Leon, C. F., Bennett, D. A., Bienias, J. L., and Evans, D. A. (2004). Depressive symptoms and cognitive decline in a community population of older persons. J. Neurol. Neurosurg. Psychiatr. 75, 126-129.